HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zitzmann, S. Articles by Haberkorn, U. Search for Related Content PubMed PubMed Citation Articles by Zitzmann, S. Articles by Haberkorn, U.

Identification of a New Prostate-Specific Cyclic Peptide with the Bacterial FliTrx System

¹ Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
² Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany
³ Department of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany

Peptides are useful tools for directing radioisotopes into tumors. We evaluated the ability of a bacterial peptide display system to isolate new prostate tumor-specific peptides. Methods: We used the bacterial FliTrx system to identify a new cyclic peptide that binds to prostate carcinoma. Serum stability and binding affinities of the ¹²⁵I-labeled peptide were tested. Furthermore, the ¹³¹I-labeled peptide was used to evaluate its biodistribution. Results: Several peptides showing a potential consensus motif were identified. The new peptide MM-2 is stable in serum for up to 24 h. It binds to PC-3 cells, and this binding can be inhibited more than 70% with the unlabeled peptide. Binding to human umbilical vein endothelial cells (HUVECs) and PNT-2 cells is weaker, and competition (27%) in HUVECs is less efficient. The biodistribution showed moderate accumulation in tumor. Conclusion: Bacterial peptide display, an alternative to phage peptide display, can allow the identification of specific binding and stable peptides.

Key Words: tumor targeting • prostate carcinoma • FliTrx bacterial peptide display

Related articles in JNM:

THIS MONTH IN JNM

JNM 2005 46: 8a-9a. [Full Text]  

This article has been cited by other articles:

				S. Afshar, T. Asai, and S. L. Morrison Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer Mol. Cancer Ther., January 1, 2009; 8(1): 185 - 193. [Abstract] [Full Text] [PDF]

				W. Yang, D. Luo, S. Wang, R. Wang, R. Chen, Y. Liu, T. Zhu, X. Ma, R. Liu, G. Xu, et al. TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis Clin. Cancer Res., September 1, 2008; 14(17): 5494 - 5502. [Abstract] [Full Text] [PDF]

				V. Tolmachev, F. Y. Nilsson, C. Widstrom, K. Andersson, D. Rosik, L. Gedda, A. Wennborg, and A. Orlova 111In-Benzyl-DTPA-ZHER2:342, an Affibody-Based Conjugate for In Vivo Imaging of HER2 Expression in Malignant Tumors J. Nucl. Med., May 1, 2006; 47(5): 846 - 853. [Abstract] [Full Text] [PDF]